The DOI matches its Crossref record; 107 of the 107 references it cites were found in a registry or an index.
Current treatment strategies for inhibiting mTOR in cancer
Open accessAbstract
Mammalian target of rapamycin (mTOR) is a Ser/Thr kinase that regulates a wide range of functions, including cell growth, proliferation, survival, autophagy, metabolism, and cytoskeletal organization. mTOR activity is dysregulated in several human disorders, including cancer. The crucial role of mTOR in cancer cell biology has stimulated interest in mTOR inhibitors, placing mTOR on the radar of the pharmaceutical industry. Several mTOR inhibitors have already undergone clinical trials for treating tumors, without great success, although mTOR inhibitors are approved for the treatment of some types of cancer, including advanced renal cell carcinoma. However, the role of mTOR inhibitors in cancer treatment continues to evolve as new compounds are continuously being disclosed. Here we review the three classes of mTOR inhibitors currently available for treating cancer patients. Moreover, we highlight efforts to identify markers of resistance and sensitivity to mTOR inhibition that could prove useful in the emerging field of personalized medicine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
mTOR Signaling in Growth Control and Disease
Laplante, M., & Sabatini, D. M. (2012) · Cell · doi:10.1016/j.cell.2012.03.017 · Cited by 8,509
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
Hudes, G., Carducci, M., Tomczak, P., Dutcher, J., Figlin, R., Kapoor, A., Staroslawska, E., Sosman, J., McDermott, D., Bodrogi, I., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066838 · Cited by 3,647
Everolimus for Advanced Pancreatic Neuroendocrine Tumors
Yao, J. C., Shah, M. H., Ito, T., Bohas, C. L., Wolin, E. M., Van Cutsem, E., Hobday, T. J., Okusaka, T., Capdevila, J., de Vries, E. G. E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009290 · Cited by 2,876
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
Baselga, J., Campone, M., Piccart, M., Burris, H. A., Rugo, H. S., Sahmoud, T., Noguchi, S., Gnant, M., Pritchard, K. I., Lebrun, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109653 · Cited by 2,863
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561
Prolonged Rapamycin Treatment Inhibits mTORC2 Assembly and Akt/PKB
Sarbassov, D. D., Ali, S. M., Sengupta, S., Sheen, J.-H., Hsu, P. P., Bagley, A. F., Markhard, A. L., & Sabatini, D. M. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.03.029 · Cited by 2,365
The Tuberous Sclerosis Complex
Crino, P. B., Nathanson, K. L., & Henske, E. P. (2006) · New England Journal of Medicine · doi:10.1056/nejmra055323 · Cited by 1,793
Guba, M., von Breitenbuch, P., Steinbauer, M., Koehl, G., Flegel, S., Hornung, M., Bruns, C. J., Zuelke, C., Farkas, S., Anthuber, M., et al. (2002) · Nature Medicine · doi:10.1038/nm0202-128 · Cited by 1,739
A unifying model for mTORC1-mediated regulation of mRNA translation
Thoreen, C. C., Chantranupong, L., Keys, H. R., Wang, T., Gray, N. S., & Sabatini, D. M. (2012) · Nature · doi:10.1038/nature11083 · Cited by 1,477
Carracedo, A., Ma, L., Teruya-Feldstein, J., Rojo, F., Salmena, L., Alimonti, A., Egia, A., Sasaki, A. T., Thomas, G., Kozma, S. C., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34739 · Cited by 1,381
Rapamycin: one drug, many effects
Li, J., Kim, S. G., & Blenis, J. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.01.001 · Cited by 1,287
Regulation of the mTOR Complex 1 Pathway by Nutrients, Growth Factors, and Stress
Sengupta, S., Peterson, T. R., & Sabatini, D. M. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.026 · Cited by 1,241
Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells
Yilmaz, Ö. H., Valdez, R., Theisen, B. K., Guo, W., Ferguson, D. O., Wu, H., & Morrison, S. J. (2006) · Nature · doi:10.1038/nature04703 · Cited by 1,113
Curatolo, P., Bombardieri, R., & Jozwiak, S. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61279-9 · Cited by 1,088
Hsu, P. P., Kang, S. A., Rameseder, J., Zhang, Y., Ottina, K. A., Lim, D., Peterson, T. R., Choi, Y., Gray, N. S., Yaffe, M. B., et al. (2011) · Science · doi:10.1126/science.1199498 · Cited by 1,084
Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2
Feldman, M. E., Apsel, B., Uotila, A., Loewith, R., Knight, Z. A., Ruggero, D., & Shokat, K. M. (2009) · PLoS Biology · doi:10.1371/journal.pbio.1000038 · Cited by 1,082
Making new contacts: the mTOR network in metabolism and signalling crosstalk
Shimobayashi, M., & Hall, M. N. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3757 · Cited by 1,053
PI3K/AKT signaling pathway and cancer: An updated review
Martini, M., De Santis, M. C., Braccini, L., Gulluni, F., & Hirsch, E. (2014) · Annals of Medicine · doi:10.3109/07853890.2014.912836 · Cited by 1,020
Everolimus for Subependymal Giant-Cell Astrocytomas in Tuberous Sclerosis
Krueger, D. A., Care, M. M., Holland, K., Agricola, K., Tudor, C., Mangeshkar, P., Wilson, K. A., Byars, A., Sahmoud, T., & Franz, D. N. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001671 · Cited by 1,006
Rapamycin passes the torch: a new generation of mTOR inhibitors
Benjamin, D., Colombi, M., Moroni, C., & Hall, M. N. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3531 · Cited by 989
AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity
Chandarlapaty, S., Sawai, A., Scaltriti, M., Rodrik-Outmezguine, V., Grbovic-Huezo, O., Serra, V., Majumder, P. K., Baselga, J., & Rosen, N. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.10.031 · Cited by 967
Genome Sequencing Identifies a Basis for Everolimus Sensitivity
Iyer, G., Hanrahan, A. J., Milowsky, M. I., Al-Ahmadie, H., Scott, S. N., Janakiraman, M., Pirun, M., Sander, C., Socci, N. D., Ostrovnaya, I., et al. (2012) · Science · doi:10.1126/science.1226344 · Cited by 690
Activation of mTORC2 by Association with the Ribosome
Zinzalla, V., Stracka, D., Oppliger, W., & Hall, M. N. (2011) · Cell · doi:10.1016/j.cell.2011.02.014 · Cited by 654
Hess, G., Herbrecht, R., Romaguera, J., Verhoef, G., Crump, M., Gisselbrecht, C., Laurell, A., Offner, F., Strahs, A., Berkenblit, A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.7977 · Cited by 641
The NF1 tumor suppressor critically regulates TSC2 and mTOR
Johannessen, C. M., Reczek, E. E., James, M. F., Brems, H., Legius, E., & Cichowski, K. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503224102 · Cited by 601
Cloughesy, T. F., Yoshimoto, K., Nghiemphu, P., Brown, K., Dang, J., Zhu, S., Hsueh, T., Chen, Y., Wang, W., Youngkin, D., et al. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050008 · Cited by 593
A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma
Fan, Q.-W., Knight, Z. A., Goldenberg, D. D., Yu, W., Mostov, K. E., Stokoe, D., Shokat, K. M., & Weiss, W. A. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.03.029 · Cited by 585
Chen, J., Zheng, X. F., Brown, E. J., & Schreiber, S. L. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.11.4947 · Cited by 556
Rapalogs and mTOR inhibitors as anti-aging therapeutics
Lamming, D. W., Ye, L., Sabatini, D. M., & Baur, J. A. (2013) · Journal of Clinical Investigation · doi:10.1172/jci64099 · Cited by 531
André, F., O'Regan, R., Ozguroglu, M., Toi, M., Xu, B., Jerusalem, G., Masuda, N., Wilks, S., Arena, F., Isaacs, C., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70138-x · Cited by 493
Phosphatase: PP2A structural importance, regulation and its aberrant expression in cancer
Seshacharyulu, P., Pandey, P., Datta, K., & Batra, S. K. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.02.036 · Cited by 481
Tabernero, J., Rojo, F., Calvo, E., Burris, H., Judson, I., Hazell, K., Martinelli, E., Cajal, S. R. Y., Jones, S., Vidal, L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.5482 · Cited by 474
Picking the Point of Inhibition: A Comparative Review of PI3K/AKT/mTOR Pathway Inhibitors
Dienstmann, R., Rodon, J., Serra, V., & Tabernero, J. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0639 · Cited by 462
Grabiner, B. C., Nardi, V., Birsoy, K., Possemato, R., Shen, K., Sinha, S., Jordan, A., Beck, A. H., & Sabatini, D. M. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0929 · Cited by 450
mTOR Kinase Inhibition Causes Feedback-Dependent Biphasic Regulation of AKT Signaling
Rodrik-Outmezguine, V. S., Chandarlapaty, S., Pagano, N. C., Poulikakos, P. I., Scaltriti, M., Moskatel, E., Baselga, J., Guichard, S., & Rosen, N. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0085 · Cited by 442
mTOR and autophagy: A dynamic relationship governed by nutrients and energy
Dunlop, E. A., & Tee, A. R. (2014) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2014.08.006 · Cited by 441
PI 3-kinase related kinases: ‘big’ players in stress-induced signaling pathways
Abraham, R. T. (2004) · DNA Repair · doi:10.1016/j.dnarep.2004.04.002 · Cited by 440
The Four Faces of Autophagy: Implications for Cancer Therapy
Gewirtz, D. A. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2966 · Cited by 435
mTORC1 Phosphorylation Sites Encode Their Sensitivity to Starvation and Rapamycin
Kang, S. A., Pacold, M. E., Cervantes, C. L., Lim, D., Lou, H. J., Ottina, K., Gray, N. S., Turk, B. E., Yaffe, M. B., & Sabatini, D. M. (2013) · Science · doi:10.1126/science.1236566 · Cited by 431
mTOR and cancer: many loops in one pathway
Efeyan, A., & Sabatini, D. M. (2010) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2009.10.007 · Cited by 430
Rangwala, R., Chang, Y. C., Hu, J., Algazy, K. M., Evans, T. L., Fecher, L. A., Schuchter, L. M., Torigian, D. A., Panosian, J. T., Troxel, A. B., et al. (2014) · Autophagy · doi:10.4161/auto.29119 · Cited by 424
Nutrient Sensing, Metabolism, and Cell Growth Control
Yuan, H.-X., Xiong, Y., & Guan, K.-L. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.01.019 · Cited by 361
Combined Targeted Treatment to Eliminate Tumorigenic Cancer Stem Cells in Human Pancreatic Cancer
Mueller, M., Hermann, P. C., Witthauer, J., Rubio–Viqueira, B., Leicht, S. F., Huber, S., Ellwart, J. W., Mustafa, M., Bartenstein, P., D'Haese, J. G., et al. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.05.053 · Cited by 348
Di Nicolantonio, F., Arena, S., Tabernero, J., Grosso, S., Molinari, F., Macarulla, T., Russo, M., Cancelliere, C., Zecchin, D., Mazzucchelli, L., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci37539 · Cited by 343
Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor
Janes, M. R., Limon, J. J., So, L., Chen, J., Lim, R. J., Chavez, M. A., Vu, C., Lilly, M. B., Mallya, S., Ong, S. T., et al. (2010) · Nature Medicine · doi:10.1038/nm.2091 · Cited by 337
Krop, I., Demuth, T., Guthrie, T., Wen, P. Y., Mason, W. P., Chinnaiyan, P., Butowski, N., Groves, M. D., Kesari, S., Freedman, S. J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.1540 · Cited by 318
PTEN function: the long and the short of it
Hopkins, B. D., Hodakoski, C., Barrows, D., Mense, S. M., & Parsons, R. E. (2014) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2014.02.006 · Cited by 309
McCubrey, J. A., Steelman, L. S., Chappell, W. H., Abrams, S. L., Montalto, G., Cervello, M., Nicoletti, F., Fagone, P., Malaponte, G., Mazzarino, M. C., et al. (2012) · Oncotarget · doi:10.18632/oncotarget.652 · Cited by 306
Self-citationImplementing personalized cancer genomics in clinical trials
Simon, R., & Roychowdhury, S. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3979 · Cited by 301
LKB1 and AMPK and the cancer-metabolism link - ten years after
Hardie, D. G., & Alessi, D. R. (2013) · BMC Biology · doi:10.1186/1741-7007-11-36 · Cited by 301
Ribosomal protein S6 kinase activity controls the ribosome biogenesis transcriptional program
Chauvin, C., Koka, V, Nouschi, A., Mieulet, V, Hoareau-Aveilla, C., Dreazen, A., Cagnard, N., Carpentier, W., Kiss, T., Meyuhas, O., et al. (2014) · Oncogene · doi:10.1038/onc.2012.606 · Cited by 282
Wagle, N., Grabiner, B. C., Van Allen, E. M., Hodis, E., Jacobus, S., Supko, J. G., Stewart, M., Choueiri, T. K., Gandhi, L., Cleary, J. M., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0353 · Cited by 281
AMPK: A Contextual Oncogene or Tumor Suppressor?
Liang, J., & Mills, G. B. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3876 · Cited by 252
TOR Mutations Confer Rapamycin Resistance by Preventing Interaction with FKBP12-Rapamycin
Lorenz, M. C., & Heitman, J. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.46.27531 · Cited by 238
CCI‐779 in metastatic melanoma: A Phase II trial of the California Cancer Consortium
Margolin, K., Longmate, J., Baratta, T., Synold, T., Christensen, S., Weber, J., Gajewski, T., Quirt, I., & Doroshow, J. H. (2005) · Cancer · doi:10.1002/cncr.21265 · Cited by 227
Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer
Sato, T., Nakashima, A., Guo, L., Coffman, K., & Tamanoi, F. (2010) · Oncogene · doi:10.1038/onc.2010.28 · Cited by 214
Ilic, N., Utermark, T., Widlund, H. R., & Roberts, T. M. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1108237108 · Cited by 211
Martelli, A. M., Evangelisti, C., Chappell, W., Abrams, S. L., Bäsecke, J., Stivala, F., Donia, M., Fagone, P., Nicoletti, F., Libra, M., et al. (2011) · Leukemia · doi:10.1038/leu.2011.46 · Cited by 204
Self-citationTORC1 Is Essential for NF1-Associated Malignancies
Johannessen, C. M., Johnson, B. W., Williams, S. M. G., Chan, A. W., Reczek, E. E., Lynch, R. C., Rioth, M. J., McClatchey, A., Ryeom, S., & Cichowski, K. (2008) · Current Biology · doi:10.1016/j.cub.2007.11.066 · Cited by 203
Adverse events associated with mTOR inhibitors
Pallet, N., & Legendre, C. (2013) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2013.752814 · Cited by 198
Tamburini, J., Green, A. S., Bardet, V., Chapuis, N., Park, S., Willems, L., Uzunov, M., Ifrah, N., Dreyfus, F., Lacombe, C., et al. (2009) · Blood · doi:10.1182/blood-2008-10-184515 · Cited by 190
López-Lago, M. A., Okada, T., Murillo, M. M., Socci, N., & Giancotti, F. G. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.01578-08 · Cited by 184
Gil del Alcazar, C. R., Hardebeck, M. C., Mukherjee, B., Tomimatsu, N., Gao, X., Yan, J., Xie, X.-J., Bachoo, R., Li, L., Habib, A. A., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1607 · Cited by 171
Chiarini, F., Grimaldi, C., Ricci, F., Tazzari, P. L., Evangelisti, C., Ognibene, A., Battistelli, M., Falcieri, E., Melchionda, F., Pession, A., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1814 · Cited by 166
Self-citationeIF4E/4E-BP Ratio Predicts the Efficacy of mTOR Targeted Therapies
Alain, T., Morita, M., Fonseca, B. D., Yanagiya, A., Siddiqui, N., Bhat, M., Zammit, D., Marcus, V., Metrakos, P. P., Voyer, L.-A., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2395 · Cited by 165
Chapuis, N., Tamburini, J., Green, A. S., Vignon, C., Bardet, V., Neyret, A., Pannetier, M., Willems, L., Park, S., Macone, A., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1102 · Cited by 164
The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia
Willems, L., Chapuis, N., Puissant, A., Maciel, T. T., Green, A. S., Jacque, N., Vignon, C., Park, S., Guichard, S., Herault, O., et al. (2012) · Leukemia · doi:10.1038/leu.2011.339 · Cited by 159
Autophagy Suppresses RIP Kinase-Dependent Necrosis Enabling Survival to mTOR Inhibition
Bray, K., Mathew, R., Lau, A., Kamphorst, J. J., Fan, J., Chen, J., Chen, H.-Y., Ghavami, A., Stein, M. N., DiPaola, R. S., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0041831 · Cited by 159
The evolution of the TOR pathway and its role in cancer
Beauchamp, E. M., & Platanias, L. C. (2012) · Oncogene · doi:10.1038/onc.2012.567 · Cited by 158
Coordinate Autophagy and mTOR Pathway Inhibition Enhances Cell Death in Melanoma
Xie, X., White, E. P., & Mehnert, J. M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055096 · Cited by 150
Markman, B., Tabernero, J. M., Krop, I. E., Shapiro, G. I., Siu, L. L., Chen, L. C., Mita, M. M., Cuero, M. M., Stutvoet, S., Birle, D. C., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds011 · Cited by 149
Targeting Mnks for Cancer Therapy
Hou, J., Lam, F., Proud, C. G., & Wang, S. (2012) · Oncotarget · doi:10.18632/oncotarget.453 · Cited by 148
Nutrient-sensing pathways and metabolic regulation in stem cells
Ochocki, J. D., & Simon, M. C. (2013) · Journal of Cell Biology · doi:10.1083/jcb.201303110 · Cited by 140
An emerging role for TOR signaling in mammalian tissue and stem cell physiology
Russell, R. C., Fang, C., & Guan, K. (2011) · Development · doi:10.1242/dev.058230 · Cited by 136
Naing, A., Aghajanian, C. A., Raymond, É., Olmos, D., Schwartz, G., Oelmann, E. M., Grinsted, L. M., Burke, W., Taylor, R., Kaye, S. B., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.368 · Cited by 135
Martelli, A. M., Chiarini, F., Evangelisti, C., Cappellini, A., Buontempo, F., Bressanin, D., Fini, M., & McCubrey, J. A. (2012) · Oncotarget · doi:10.18632/oncotarget.477 · Cited by 122
Self-citationDubrovska, A., Elliott, J., Salamone, R. J., Kim, S., Aimone, L. J., Walker, J. R., Watson, J., Maira, S.-M., García-Echeverría, C., Cho, C. Y., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1601 · Cited by 121
Janes, M. R., Vu, C., Mallya, S., Shieh, M., Limon, J. J., Li, L., Jessen, K., Martin, M., Ren, P., Lilly, M. B., et al. (2012) · Leukemia · doi:10.1038/leu.2012.276 · Cited by 110
The mTORC1/mTORC2 inhibitor AZD2014 enhances the radiosensitivity of glioblastoma stem-like cells
Kahn, J. M., Hayman, T. J., Jamal, M., Rath, B. H., Kramp, T. R., Camphausen, K. A., & Tofilon, P. J. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not139 · Cited by 105
Evangelisti, C., Ricci, F., Tazzari, P. L., Tabellini, G., Battistelli, M., Falcieri, E., Chiarini, F., Bortul, R., Melchionda, F., Pagliaro, P., et al. (2011) · Leukemia · doi:10.1038/leu.2011.20 · Cited by 104
Self-citationGermline PTEN Mutation Cowden Syndrome: An Underappreciated Form of Hereditary Kidney Cancer
Shuch, B. M., Ricketts, C. J., Vocke, C. D., Komiya, T., Middelton, L. A., KAUFFMAN, E. C., Merino, M. J., Metwalli, A. R., Dennis, P. A., & Linehan, W. M. (2013) · The Journal of Urology · doi:10.1016/j.juro.2013.06.012 · Cited by 104
Selective targeting of human colon cancer stem-like cells by the mTOR inhibitor Torin-1
Francipane, M. G., & Lagasse, E. (2013) · Oncotarget · doi:10.18632/oncotarget.1310 · Cited by 97
Wang, C., Cigliano, A., Delogu, S., Armbruster, J., Dombrowski, F., Evert, M., Chen, X., & Calvisi, D. F. (2013) · Cell Cycle · doi:10.4161/cc.25099 · Cited by 96
Ducker, G. S., Atreya, C. E., Simko, J. P., Hom, Y. K., Matli, M. R., Benes, C. H., Hann, B. C., Nakakura, E. K., Bergsland, E. K., Donner, D. B., et al. (2013) · Oncogene · doi:10.1038/onc.2013.92 · Cited by 92
Alers, S., Löffler, A. S., Wesselborg, S., & Stork, B. (2012) · Cell Communication and Signaling · doi:10.1186/1478-811x-10-7 · Cited by 92
CXCR4 and CXCR7 transduce through mTOR in human renal cancer cells
Ieranò, C., Santagata, S., Napolitano, M., Guardia, F., Grimaldi, A., Antignani, E., Botti, G., Consales, C., Riccio, A., Nanayakkara, M., et al. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.269 · Cited by 86
Tailoring mTOR-Based Therapy: Molecular Evidence and Clinical Challenges
Santulli, G., & Totary-Jain, H. (2013) · Pharmacogenomics · doi:10.2217/pgs.13.143 · Cited by 84
PI3K/mTOR inhibition upregulates NOTCH-MYC signalling leading to an impaired cytotoxic response
Shepherd, C., Banerjee, L., Cheung, C. W., Mansour, M. R., Jenkinson, S., Gale, R. E., & Khwaja, A. (2012) · Leukemia · doi:10.1038/leu.2012.285 · Cited by 76
Pancreatic tumours escape from translational control through 4E-BP1 loss
Martineau, Y., Azar, R., Müller, D., Lasfargues, C., Khawand, S. E., Anesia, R., Pelletier, J., Bousquet, C., & Pyronnet, S. (2013) · Oncogene · doi:10.1038/onc.2013.100 · Cited by 75
Kapoor, A., & Figlin, R. A. (2009) · Cancer · doi:10.1002/cncr.24409 · Cited by 73
Bertacchini, J., Guida, M., Accordi, B., Mediani, L., Martelli, A. M., Barozzi, P., Petricoin, E. F., Liotta, L. A., Milani, G., Giordan, M., et al. (2014) · Leukemia · doi:10.1038/leu.2014.123 · Cited by 69
Self-citationHassan, B., Akçakanat, A., Sangai, T., Evans, K. W., Adkins, F. C., Eterovic, A. K., Zhao, H., Chen, K., Chen, H., Do, K.-A., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2337 · Cited by 63
Schroeder, R. D., Angelo, L. S., & Kurzrock, R. (2013) · Oncotarget · doi:10.18632/oncotarget.1557 · Cited by 61
Cotargeting the PI3K and RAS Pathways for the Treatment of Neuroendocrine Tumors
Valentino, J. D., Li, J., Zaytseva, Y. Y., Mustain, W. C., Elliott, V. A., Kim, J. T., Harris, J. W., Campbell, K., Weiss, H. L., Wang, C., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1897 · Cited by 61
Oncology Drug Discovery: Planning a Turnaround
Toniatti, C., Jones, P. S., Graham, H., Pagliara, B., & Draetta, G. F. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0452 · Cited by 59
Molecular Therapies for Tuberous Sclerosis and Neurofibromatosis
Franz, D. N., & Weiss, B. D. (2012) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-012-0269-4 · Cited by 58
Kim, A., Lee, J. J., Lee, S., Kim, C., Lee, S., Jang, W., & Park, S. (2013) · International Journal of Cancer · doi:10.1002/ijc.28073 · Cited by 54
Yang, F., Qian, X.-J., Qin, W., Deng, R., Wu, X.-Q., Qin, J., Feng, G., & Zhu, X. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059879 · Cited by 53
MTOR inhibition attenuates DNA damage and apoptosis through autophagy-mediated suppression of CREB1
Wang, Y., Hu, Z., Liu, Z., Chen, R., Peng, H., Guo, J., Chen, X., & Zhang, H. (2013) · Autophagy · doi:10.4161/auto.26447 · Cited by 51
Resistance to mTOR Kinase Inhibitors in Lymphoma Cells Lacking 4EBP1
Mallya, S., Fitch, B. A., Lee, J. S., So, L., Janes, M. R., & Fruman, D. A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0088865 · Cited by 42
Targeting phosphatidylinositol 3 kinase (PI3K)-Akt beyond rapalogs
Ogita, S., & LoRusso, P. M. (2011) · Targeted Oncology · doi:10.1007/s11523-011-0176-7 · Cited by 40
Altman, J. K., Glaser, H., Sassano, A., Joshi, S. S., Ueda, T., Watanabe‐Fukunaga, R., Fukunaga, R., Tallman, M. S., & Platanias, L. C. (2010) · Molecular Pharmacology · doi:10.1124/mol.110.064642 · Cited by 38
Martelli, A. M., Tabellini, G., Ricci, F., Evangelisti, C., Chiarini, F., Bortul, R., McCubrey, J. A., & Manzoli, F. A. (2011) · Advances in Biological Regulation · doi:10.1016/j.advenzreg.2011.09.019 · Cited by 23
Self-citationNext generation of mammalian target of rapamycin inhibitors for the treatment of cancer
Nelson, V. M., Altman, J. K., & Platanias, L. C. (2013) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2013.787066 · Cited by 20
Atreya, C. E., Ducker, G. S., Feldman, M. E., Bergsland, E. K., Warren, R. S., & Shokat, K. M. (2012) · Investigational New Drugs · doi:10.1007/s10637-012-9793-y · Cited by 19
Efficacious Intermittent Dosing of a Novel JAK2 Inhibitor in Mouse Models of Polycythemia Vera
Kraus, M., Wang, Y., Aleksandrowicz, D., Bachman, E. S., Szewczak, A. A., Walker, D., Xu, L. S., Bouthillette, M., Childers, K. K., Dolinski, B. M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0037207 · Cited by 15
Cited by
Cancer metabolism: a therapeutic perspective
Martinez-Outschoorn, U. E., Peiris-Pagés, M., Pestell, R. G., Sotgia, F., & Lisanti, M. P. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.60 · Cited by 1,505
FDA-approved small-molecule kinase inhibitors
Wu, P., Nielsen, T. E., & Clausen, M. H. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.04.005 · Cited by 1,013
Panwar, V., Singh, A., Bhatt, M., Tonk, R. K., Azizov, S., Raza, A. S., Sengupta, S., Kumar, D., & Garg, M. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01608-z · Cited by 967
Targeting mTOR for cancer therapy
Hua, H., Kong, Q., Zhang, H., Wang, J., Luo, T., & Jiang, Y. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0754-1 · Cited by 899
Regulation of innate immune cell function by mTOR
Weichhart, T., Hengstschläger, M., & Linke, M. (2015) · Nature Reviews Immunology · doi:10.1038/nri3901 · Cited by 830
Metadata
- Authors
- Chiarini, F., Evangelisti, C., McCubrey, J. A., & Martelli, A. M.
- Venue
- Trends in Pharmacological Sciences
- Publisher
- Elsevier BV
- Published
- 2015-02
- Volume
- 36
- Issue
- 2
- Pages
- 124-135
- ISSN
- 0165-6147 (ISSN-L)
- OpenAlex
- W1980402007
- Cited by
- 275
- References
- 107
- FWCI
- 2.22
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.